New Report Unveils Hottest Industry Trends in Life Sciences Sector 2014
george james Ltd, a leading provider of recruitment, training and corporate development services to the scientific industry, has announced the availability of a new report “Life Science Trends 2014,” which outlines trends and innovations in the life sciences industry. Written in conjunction with Carlyle Conlan, the report encompasses drugs, biologics, devices and diagnostics sectors, summarising a variety of the most up to date industry news. It demonstrates significant advances in the industry from the past year and highlights observations about developments of interest throughout the year ahead. To obtain a free copy of the report please click here.
Designed as a meaningful “quick read” whitepaper, the report is separated into several macro headers: Research and Innovation, Fundamental Trends, Investing and Deal Making, Regulatory and Government and Health Care. The report is essential reading for those working in the pharmaceutical and biotech industries who are not only looking for an overall summary, but a resource to explore deeper, dependant on the individual interest of the reader.
In addition, the essential annual report also includes an exclusive feature article “Big Data in the Life Sciences”, which highlights commentary and interviews from several key senior industry professionals involved in big data breakthroughs in the life sciences sector. This feature article demonstrates how the enormous increase in data volume from segments like sequencing and systems biology, coupled with trends in pre-competitive data sharing and advanced computing frameworks, is in the early stages of providing robust signals, that will ultimately decrease the cost of drug development and maximise the industry’s return on investment.
Neil Burns, Founding Director at george james Ltd, said: “We are very pleased that this report has been published and is now easily available to download from our website. It has been structured in a way which is easy to read for industry professionals in pharma and biotech to keep informed but still can be researched further. We at george james strive help our customers achieve their core goals and specialisation and hope this report offers premium research of value to the life sciences sector.”
Don Alexander, Practice Head and Vice President, Life Sciences at Carlyle Conlan, comments: “We are very pleased to be able to, with the support of George James, have a report available for the public to read which covers such a wide range of articles across pertinent areas such as Health Care, Research and Innovation. What makes our report different is that an early version is sent to CEOs, venture capitalists and other industry experts for review before its final release and created using both primary and secondary data. We invite you to review the information contained in the report which we hope you will find relevant and interesting.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance